Mar 27, 2018
Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Mar 23, 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Mar 12, 2018
Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of GI Cancer Trial
Feb 16, 2018
PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
Jan 24, 2018
Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
Jan 18, 2018
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Jan 03, 2018
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 23, 2017
Bringing Access to Biologics
Dec 07, 2017
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Dec 04, 2017
Caris Life Sciences Announces Presentations at the 2017 San Antonio Breast Cancer Symposium Highlighting Precision Medicine Advances
Dec 04, 2017
Caris Life Sciences Announces Presentations at the 2017 San Antonio Breast Cancer Symposium Highlighting Precision Medicine Advances
Dec 01, 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Nov 30, 2017
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging
Nov 22, 2017
New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal
Nov 15, 2017
TapImmune Provides Third Quarter 2017 Corporate and Clinical Update
Nov 14, 2017
Data at SABCS and ASH Demonstrate Daiichi Sankyo Commitment to Advancing Science in Breast and Blood Cancer
Oct 30, 2017
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
Oct 10, 2017
Diplomat Selected to Dispense VERZENIO(TM) for Breast Cancer
Sep 28, 2017
FDA approves new treatment for certain advanced or metastatic breast cancers
Sep 18, 2017
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer